Drug Profile
Research programme: anticancer bioconjugates (BIOCON) - Adamed
Alternative Names: BIOCONLatest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Adamed
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Cancer in Poland (unspecified route) (Adamed website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Poland
- 20 Jul 2016 Preclinical trials in Cancer in Poland (unspecified route)